+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vaginal Antifungals Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 250 Pages
  • December 2023
  • Region: Global
  • Fairfield Market Research
  • ID: 5916035
Description Jump to:
The global vaginal antifungals market is experiencing substantial growth, driven by the prevalence of vaginal infections such as candidiasis among women worldwide. A recent report reveals that the market was valued at US$ 1.08 billion in 2024 and is projected to reaching a size of US$ 1.41 billion by the end of 2031.

Rising Prevalence of Candidal Vulvovaginitis Propels Market Demand

Vulvovaginitis, characterized by inflammation of the vulva and vagina, is a common concern among women of reproductive age. StatPearls Publishing (2022) reports that one-third of all vulvovaginitis cases in this demographic result from candidal vulvovaginitis. Furthermore, an astounding 70% of women have experienced candidal vulvovaginitis at some point in their lives. Recurrent candidal vulvovaginitis affects approximately 8% of women, underscoring the need for effective treatment options and providing manufacturers with significant growth opportunities in the global market.

Innovative Drug Delivery Systems Open New Avenues for Expansion

While antimicrobial therapies have traditionally been the standard treatment for vaginal infections, challenges such as side effects, microbial resistance, and infection recurrences have spurred innovation in drug delivery methods. Efforts are focused on developing localized treatment solutions that can remain in place and continuously release active ingredients. Nanosystems, including nanoparticles, liposomes, and micelles with variable surface properties, are being explored to optimize drug delivery, absorption, retention, and biodistribution in vulvovaginal tissues. These advancements present lucrative opportunities for expansion in drug development and manufacturing for vaginal antifungal suppliers, auguring well for overall market growth in the coming years.

Challenges to Vaginal Antifungal Sales

The market for vaginal antifungals faces certain challenges, primarily stemming from the limitations of existing drug delivery systems. Topical forms such as suppositories, aerosols, gels, ovules, creams, lotions, and tablets have shown limited efficacy due to poor permeability of the vaginal wall and rapid removal from the vaginal canal, influenced by hormonal factors. Frequent local administrations are often required, leading to increased adverse effects and decreased patient compliance. Self-medication practices and associated adverse events, along with misdiagnosis and treatment delays, further constrain market growth.

Country-wise Insights

  • United States: The US stands as a prominent market for vaginal antifungals, driven by rising awareness among the public about treatment options and the presence of reimbursement reforms within the healthcare system, which facilitate market growth.
  • China: China's rapidly growing economy, expanding consumer base, rising per capita income, increased personal hygiene awareness, and improved healthcare access contribute to the growth of the vaginal antifungals market. Limited data on the prevalence of vaginal fungal infections offers opportunities for research and development in the country.
  • Germany: Recurrent vaginal candidiasis is prevalent in Germany, affecting a significant portion of the population. The availability of effective antimycotic medications and successful management of acute cases are factors driving the growth of the vaginal antifungals market in the country.

Competitive Landscape

The market for vaginal antifungals is characterized by fragmentation, with key players investing in research and development, expanding product portfolios, and forming strategic mergers and partnerships to launch innovative products.

Notable companies in the industry include,
  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC Medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

  • Fluconazole
  • Nystatin
  • Flucytosine
  • Clotrimazole
  • Ketoconazole
  • Terbinafine
  • Others

By Route of Administration:

  • Oral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)


This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Vaginal Antifungals Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Vaginal Antifungals Market Outlook, 2018 - 2031
3.1. Global Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Fluconazole
3.1.1.2. Nystatin
3.1.1.3. Flucytosine
3.1.1.4. Clotrimazole
3.1.1.5. Ketoconazole
3.1.1.6. Terbinafine
3.1.1.7. Others
3.2. Global Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Topical
3.3. Global Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. Online Pharmacies
3.4. Global Vaginal Antifungals Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Vaginal Antifungals Market Outlook, 2018 - 2031
4.1. North America Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Fluconazole
4.1.1.2. Nystatin
4.1.1.3. Flucytosine
4.1.1.4. Clotrimazole
4.1.1.5. Ketoconazole
4.1.1.6. Terbinafine
4.1.1.7. Others
4.2. North America Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Oral
4.2.1.2. Topical
4.3. North America Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. Online Pharmacies
4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Vaginal Antifungals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. U.S. Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
4.4.1.2. U.S. Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.4.1.3. U.S. Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.1.4. Canada Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
4.4.1.5. Canada Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
4.4.1.6. Canada Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
4.4.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Vaginal Antifungals Market Outlook, 2018 - 2031
5.1. Europe Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Fluconazole
5.1.1.2. Nystatin
5.1.1.3. Flucytosine
5.1.1.4. Clotrimazole
5.1.1.5. Ketoconazole
5.1.1.6. Terbinafine
5.1.1.7. Others
5.2. Europe Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Oral
5.2.1.2. Topical
5.3. Europe Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. Online Pharmacies
5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Vaginal Antifungals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Germany Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.2. Germany Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.3. Germany Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.4. U.K. Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.5. U.K. Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.6. U.K. Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.7. France Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.8. France Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.9. France Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.10. Italy Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.11. Italy Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.12. Italy Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.13. Turkey Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.14. Turkey Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.15. Turkey Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.16. Russia Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.17. Russia Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.18. Russia Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.1.19. Rest of Europe Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
5.4.1.20. Rest of Europe Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
5.4.1.21. Rest of Europe Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
5.4.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Vaginal Antifungals Market Outlook, 2018 - 2031
6.1. Asia Pacific Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Fluconazole
6.1.1.2. Nystatin
6.1.1.3. Flucytosine
6.1.1.4. Clotrimazole
6.1.1.5. Ketoconazole
6.1.1.6. Terbinafine
6.1.1.7. Others
6.2. Asia Pacific Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Oral
6.2.1.2. Topical
6.3. Asia Pacific Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. Online Pharmacies
6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Vaginal Antifungals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. China Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.2. China Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.3. China Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.4. Japan Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.5. Japan Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.6. Japan Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.7. South Korea Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.8. South Korea Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.9. South Korea Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.10. India Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.11. India Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.12. India Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.13. Southeast Asia Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.14. Southeast Asia Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.15. Southeast Asia Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.1.16. Rest of Asia Pacific Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
6.4.1.17. Rest of Asia Pacific Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
6.4.1.18. Rest of Asia Pacific Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
6.4.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Vaginal Antifungals Market Outlook, 2018 - 2031
7.1. Latin America Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Fluconazole
7.1.1.2. Nystatin
7.1.1.3. Flucytosine
7.1.1.4. Clotrimazole
7.1.1.5. Ketoconazole
7.1.1.6. Terbinafine
7.1.1.7. Others
7.2. Latin America Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
7.2.1.1. Oral
7.2.1.2. Topical
7.3. Latin America Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. Online Pharmacies
7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Vaginal Antifungals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Brazil Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.2. Brazil Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.4.1.3. Brazil Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.4. Mexico Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.5. Mexico Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.4.1.6. Mexico Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.7. Argentina Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.8. Argentina Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.4.1.9. Argentina Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.1.10. Rest of Latin America Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
7.4.1.11. Rest of Latin America Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
7.4.1.12. Rest of Latin America Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
7.4.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Vaginal Antifungals Market Outlook, 2018 - 2031
8.1. Middle East & Africa Vaginal Antifungals Market Outlook, by Drug, Value (US$ Bn), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Fluconazole
8.1.1.2. Nystatin
8.1.1.3. Flucytosine
8.1.1.4. Clotrimazole
8.1.1.5. Ketoconazole
8.1.1.6. Terbinafine
8.1.1.7. Others
8.2. Middle East & Africa Vaginal Antifungals Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Oral
8.2.1.2. Topical
8.3. Middle East & Africa Vaginal Antifungals Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Online Pharmacies
8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Vaginal Antifungals Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. GCC Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.2. GCC Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1.3. GCC Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.4. South Africa Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.5. South Africa Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1.6. South Africa Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.7. Egypt Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.8. Egypt Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1.9. Egypt Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.10. Nigeria Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.11. Nigeria Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1.12. Nigeria Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.1.13. Rest of Middle East & Africa Vaginal Antifungals Market by Drug, Value (US$ Bn), 2018 - 2031
8.4.1.14. Rest of Middle East & Africa Vaginal Antifungals Market by Route of Administration, Value (US$ Bn), 2018 - 2031
8.4.1.15. Rest of Middle East & Africa Vaginal Antifungals Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
8.4.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. By Distribution Channel vs by Route of Administration Heat map
9.2. Manufacturer vs by Route of Administration Heatmap
9.3. Company Market Share Analysis, 2023
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Pfizer Inc.
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Bausch Health Companies Inc
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. ANI Pharmaceuticals, Inc.
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Hikma Pharmaceuticals Plc
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Lupin Limited
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Mycovia Pharmaceuticals, Inc.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Glenmark Pharmaceuticals Limited
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Unique Pharmaceuticals
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. PEPTONIC medical AB
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Aurobindo Pharma Limited
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Dr. Reddy's Laboratories
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. SCYNEXIS, Inc.
9.5.12.1. Company Overview
9.5.12.2. Product Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
9.5.13. Basilea Pharmaceutica Ltd.
9.5.13.1. Company Overview
9.5.13.2. Product Portfolio
9.5.13.3. Financial Overview
9.5.13.4. Business Strategies and Development
9.5.14. Astellas Pharma Inc.
9.5.14.1. Company Overview
9.5.14.2. Product Portfolio
9.5.14.3. Financial Overview
9.5.14.4. Business Strategies and Development
9.5.15. Grupo Ferrer Internacional, S.A.
9.5.15.1. Company Overview
9.5.15.2. Product Portfolio
9.5.15.3. Financial Overview
9.5.15.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Antifungals Global Market Report 2024 - Product Image

Antifungals Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032 - Product Image

Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Antifungal Drugs Market by Infection Type, Type, Form, Therapeutic Indications - Global Forecast 2025-2030 - Product Image

Antifungal Drugs Market by Infection Type, Type, Form, Therapeutic Indications - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Antifungal Drugs - Global Strategic Business Report - Product Image

Antifungal Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class (Azoles, Polyenes), Indication (Dermatophytosis, Aspergillosis), Dosage Form, Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class (Azoles, Polyenes), Indication (Dermatophytosis, Aspergillosis), Dosage Form, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.